Trials / Withdrawn
WithdrawnNCT01724138
An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 2 Years – 71 Years
- Healthy volunteers
- Not accepted
Summary
To characterize the PK of deferasirox in pediatric β-thalassemia major patients aged from 2 to less than 6 years old, when administrated with a fixed starting dose of 20 mg/kg/day.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deferasirox | Patients will start their deferasirox treatment with a dose of 20 mg/kg/day. |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2014-04-01
- Completion
- 2014-10-01
- First posted
- 2012-11-09
- Last updated
- 2017-04-20
Source: ClinicalTrials.gov record NCT01724138. Inclusion in this directory is not an endorsement.